FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

O.C.G.A. §26-4-114.1 makes it unlawful for a pharmacy located outside Georgia without a nonresident pharmacy permit to ship, mail or deliver prescription drug orders into the state; Board Rule 480-6-.02 implements the permit. The pharmacist-in-charge who dispenses to Georgia residents must be licensed and in good standing in the pharmacy's home state; a Georgia-licensed PIC is not required. Pharmacies that compound must submit a USP-compliance inspection report. The statute sets it at no more than 6 months before initial registration or 2 years before renewal, and the Board's Feb. 2026 application asks for a report under 2 years old from the home-state regulator or a Board-approved inspection. The Georgia Drugs and Narcotics Agency (GDNA) does not inspect out-of-state facilities. Permit holders must run a toll-free counseling line at least 6 days and 60 hours a week, and the application fee is $1,000.

The statute text was read on FindLaw (Justia blocked fetching). The Board's April 22, 2026 rule-hearing notice proposed repealing Chapter 480-48 (delivery by mail) and amending Rule 480-11-.04 and hospital rules; whether and when these were adopted was not confirmed. The nonresident application still refers to pharmacies compounding 'for practitioners to use in patient care in the practitioner's office', which conflicts with Rule 480-11-.02's ban on office-use distribution by 503A pharmacies (see office_use_503a).

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Board Rule 480-11-.02 says: 'The distribution of non-patient specific compounded preparations for office use by a practitioner, excluding veterinarians, is prohibited.' It adds that this does not affect 503B outsourcing facilities' ability to supply office use. Veterinary office or emergency supply is capped at 5% of a pharmacy's yearly compounding production; above 5% counts as manufacturing and needs a manufacturer license. Pharmacists may compound ahead of orders only based on a history of valid prescriptions within an established pharmacist/patient/prescriber relationship. GDNA's Jan. 2016 letter told in-state and nonresident pharmacies they may no longer compound for office use unless registered with FDA as 503B outsourcing facilities, which matches FDA's view.

The rule was last amended effective 5/24/2023, more than 2 years ago; no later amendment to the office-use sentence was found. The 2016 GDNA letter is possibly stale but agrees with the rule. The Board's Feb. 2026 nonresident application still asks for an inspection report from pharmacies compounding 'for practitioners to use in patient care in the practitioner's office', which looks like legacy wording.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

GDNA's January 20, 2016 letter, posted by the Board of Pharmacy, states that 'Georgia requires all 503B outsourcing facilities to be a licensed pharmacy, both in-state and non-resident' and that they must 'also hold a Georgia drug manufacturing permit as well as the pharmacy permit'. Under that letter, 503B facilities may distribute non-patient-specific office-use drugs to practitioners but not for resale. O.C.G.A. §26-4-5 defines an outsourcing facility as a compounding facility registered with FDA under section 503B. Manufacturer permits are issued under Rule 480-7-.01 after the GDNA Director certifies the applicant's qualifications.

The dual pharmacy-plus-manufacturer requirement comes from the 2016 GDNA letter, which is possibly stale (older than 2 years). Neither Rule 480-7-.01 (amended eff. 8/13/2024) nor the other rules checked mention 503B facilities, and the Board's current forms page does not list a separate outsourcing facility application. A secondary search snippet (not fetched) indicated that 503B facilities use the Board's manufacturing application. Confirm the current credential with the Georgia Board of Pharmacy (gbp.georgia.gov, 404-651-8000).

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Georgia is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

O.C.G.A. 16-13-35(a) requires every person who dispenses controlled substances to obtain annually a registration from the State Board of Pharmacy, but subsection (g) provides that persons licensed as a physician, dentist or veterinarian to use, prescribe, dispense and administer drugs 'are registered under this article and are exempt from the registration fee and registration application requirements'. In practice a Georgia license plus a Georgia DEA registration is what is required. The exemption names physicians, dentists and veterinarians; APRNs and PAs prescribe under delegation/protocol arrangements with a physician.

Source older than 2 years - possibly stale (FindLaw text 'current as of' Mar. 28, 2024; the official Lexis-hosted code could not be opened). Statute text read via WebFetch summary of FindLaw, which quoted subsection (g) verbatim. Whether APRNs/PAs need anything beyond DEA and their delegation agreement was not confirmed - check with the Georgia Board of Pharmacy / Composite Medical Board.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Since July 1, 2018, a prescriber issuing a 'controlled medication' - defined as a Schedule II opiate or cocaine derivative under O.C.G.A. 16-13-26(1)-(2) or a benzodiazepine - must review the PDMP the first time the prescription is issued to a patient and at least every 90 days thereafter, and must note the check in the chart. Exemptions: supplies of 3 days or less and no more than 26 pills; patients in a hospital or health care facility where the drug is administered; post-outpatient-surgery supplies of 10 days or less and no more than 40 pills; terminally ill or outpatient hospice patients; and cancer treatment. Enforced by the prescriber's licensing board; the PDMP is run by the Georgia Department of Public Health.

Frequency: first prescription + at least every 90 days. Testosterone (C-III) is not caught. The Georgia rules site (rules.sos.ga.gov) refused the connection; the rule text was read on LII and matches the DPH page (last updated 4/21/2026). The statute text of O.C.G.A. 16-13-63 was not opened directly.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

O.C.G.A. 26-4-130 exempts practitioners dispensing their own prescriptions from most of the pharmacy act but requires them to meet all pharmacy recordkeeping, labeling, packaging and storage requirements and to open records to inspection. Board of Pharmacy Rule 480-28-.03 requires a practitioner who intends to dispense to notify the licensing board at license renewal with name, license number, DEA number and dispensing address; the Georgia Composite Medical Board passes this to the Board of Pharmacy. The Georgia Drugs and Narcotics Agency inspects dispensing practitioners.

Source older than 2 years - possibly stale. Official sources (rules.sos.ga.gov, gdna.georgia.gov) could not be loaded by the research tools; statute and rule text read from a 2017 law-firm compilation. Verify with the Georgia Composite Medical Board. Answer is yes because only notice is required. Compilation date taken from the file upload timestamp (Feb. 2017).

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

Out-of-state physicians who treat Georgia patients electronically need a Georgia license or a telemedicine license, which is limited to telemedicine practice (O.C.G.A. 43-34-31, 43-34-31.1; Rule 360-2-.17). Under Rule 360-3-.07 the treating clinician must have examined the patient personally, be acting at the request of a Georgia clinician who has, or be able to examine the patient using technology and peripherals equal or superior to an in-person exam. The rule does not authorize prescribing controlled substances for pain or chronic pain by electronic means, and board rules treat prescribing controlled substances based solely on an electronic consultation as unprofessional conduct. IMLC: member.

Georgia's official rule and code sites blocked the research tools, so primary text was not read. How the 'solely electronic consultation' rule applies to non-pain controlled substances such as testosterone is unclear; confirm with the Georgia Composite Medical Board.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Georgia Composite Medical Board's guidance, FAQ and rule-update pages (checked 2026-09-23) contain no statement on cosmetic injectables. Its 2026 IV statement, summarizing the Board of Nursing, says RNs and LPNs may not be the only licensed professional evaluating and treating patients in non-traditional settings, because diagnosis and treatment planning are outside nursing scope. Whether the Board of Nursing applies an individualized-order/prior-exam requirement to neuromodulators and fillers was not confirmed.

Georgia Board of Nursing documents on sos.ga.gov returned HTTP 403 to automated requests on 2026-09-23. Check with the Georgia Board of Nursing (Secretary of State).

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Georgia Composite Medical Board's IV Hydration/Therapy position statement (2026-05-07) adopts the Board of Nursing's IV Hydration Position Statement: in walk-in, mobile and drip-bar settings an RN or LPN may not be the only licensed professional evaluating and treating the patient. IV hydration, nutrients and medications may be given by an RN, or an LPN under supervision, only on a valid individualized order from a physician, NP or PA after that prescriber completes a history and physical; standing orders are not an appropriate substitute, and businesses must keep on-site policies and emergency procedures. APRNs may evaluate and order under a compliant nurse protocol agreement; the clinic may not rely on RN-only evaluation, generic standing orders, menu-based treatment or non-compliant sterile compounding (USP <797>).

The Board of Nursing's own 2024 statement (sos.ga.gov) could not be fetched (HTTP 403); its content is taken from the Medical Board's summary.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health classifies Georgia as 'Unclear (Historical)', citing O.C.G.A. §43-34-37 and Sherrer v. Hale (1982); MedPath calls it nuanced. Separately, the Medical Board's May 2026 position statement says that under O.C.G.A. §43-34-25(n) it is unlawful for a physician to be employed by an APRN they supervise, and the Board reads this to cover any compensation from an APRN or APRN-owned company for serving as delegating physician, including payment routed through 'collaborator' matching companies. NP-owned med spas therefore cannot pay their own delegating physician.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

Under the Cosmetic Laser Services Act and Board Chapter 360-35 (amended effective 2026-05-25), 'cosmetic laser services' means nonablative light-based skin care, photorejuvenation or hair removal with FDA-approved lasers or pulsed light and now also energy-based procedures using ultrasound, cryolipolysis, microwave or radiofrequency devices. A senior laser practitioner (a nurse or PA with a licence) practises under a consulting physician's protocols and may supervise assistants. Assistant laser practitioners work under a physician or senior practitioner and must have patients examined first by a consulting physician or a licensed PA/APRN laser practitioner, except that on-site supervision and a prior exam are not required for laser hair removal and pulsed-light treatments. Applicants need physician- or ACCME-taught training certificates (two for senior, three for assistant), and seniors need three years' clinical experience and a consulting physician agreement.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Georgia was not among them, but this research did not confirm its statutes. Georgia's CLIA state agency is Georgia Dept. of Community Health, Healthcare Facility Regulation Division, Diagnostic Services Unit (hfrd.diagnostic@dch.ga.gov, 404-657-5700); it can confirm whether any state license or permit applies, including to out-of-state labs.

Georgia may run its own in-state lab licensing program; this could not be confirmed from a primary source in this pass, so check with the agency before relying on CLIA alone.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Georgia's rule. Georgia's lab regulator (CLIA state agency) is Georgia Dept. of Community Health, Healthcare Facility Regulation Division, Diagnostic Services Unit (hfrd.diagnostic@dch.ga.gov, 404-657-5700). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

HB 1275 adds O.C.G.A. §43-34-49. 'Human stem cell therapy' means treatment using afterbirth placental perinatal stem cells or HCT/Ps (the definition excludes secreted or extracted products such as cell factors), and excludes cells from aborted fetuses or embryos. Cells must come from a facility that is FDA-registered, or certified by WMDA, AABB, AATB or another entity approved by the Department of Public Health, and must follow cGMP and 21 CFR 1271. Facilities must tell the physician of accreditation changes within 30 days. Ads must include a notice ('THIS NOTICE MUST BE PROVIDED TO YOU UNDER GEORGIA LAW...'), and a signed consent must state the treatment's nature, FDA status and anticipated results. IND holders and staff of FACT-, BMT CTN- or AABB-accredited institutions are exempt. Violations are subject to board discipline. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

Signed May 11, 2026 and effective July 1, 2026, per secondary sources (the as-passed text has no special effective date). The HCT/P definition excludes 'secreted or extracted human products, such as ... cell factors', so exosome and growth-factor products are likely outside the law.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Georgia does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.